Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is ...

On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

Patients with COPD are at increased risk for infections, making avoidance and effective treatments key in management.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

The BREATHE-3 trial hopes to determine the safety and impact of a novel bronchoscopic device on lung function in adults with ...

AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

(StatePoint) More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

In 2021, an estimated 14 million adults in the United States reported a diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema. If you’re not sure what the ...